Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11026 - 11050 of 12842 in total
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
Investigational
Investigational
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
Investigational
Investigational
Investigational
Investigational
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Investigational
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Investigational
Investigational
Investigational
Investigational
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Investigational
Displaying drugs 11026 - 11050 of 12842 in total